1. Home
  2. RPRX vs SUI Comparison

RPRX vs SUI Comparison

Compare RPRX & SUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RPRX
  • SUI
  • Stock Information
  • Founded
  • RPRX 1996
  • SUI 1975
  • Country
  • RPRX United States
  • SUI United States
  • Employees
  • RPRX N/A
  • SUI N/A
  • Industry
  • RPRX Biotechnology: Pharmaceutical Preparations
  • SUI Real Estate Investment Trusts
  • Sector
  • RPRX Health Care
  • SUI Real Estate
  • Exchange
  • RPRX Nasdaq
  • SUI Nasdaq
  • Market Cap
  • RPRX 16.2B
  • SUI 15.5B
  • IPO Year
  • RPRX 2020
  • SUI 1993
  • Fundamental
  • Price
  • RPRX $38.51
  • SUI $126.38
  • Analyst Decision
  • RPRX Strong Buy
  • SUI Buy
  • Analyst Count
  • RPRX 3
  • SUI 14
  • Target Price
  • RPRX $46.00
  • SUI $137.57
  • AVG Volume (30 Days)
  • RPRX 3.2M
  • SUI 786.7K
  • Earning Date
  • RPRX 11-05-2025
  • SUI 10-29-2025
  • Dividend Yield
  • RPRX 2.28%
  • SUI 3.29%
  • EPS Growth
  • RPRX N/A
  • SUI 324.78
  • EPS
  • RPRX 1.75
  • SUI 7.94
  • Revenue
  • RPRX $2,349,844,000.00
  • SUI $3,236,900,000.00
  • Revenue This Year
  • RPRX $36.16
  • SUI N/A
  • Revenue Next Year
  • RPRX $2.04
  • SUI $4.73
  • P/E Ratio
  • RPRX $22.00
  • SUI $15.95
  • Revenue Growth
  • RPRX 3.70
  • SUI 32.39
  • 52 Week Low
  • RPRX $24.05
  • SUI $109.22
  • 52 Week High
  • RPRX $41.24
  • SUI $137.77
  • Technical
  • Relative Strength Index (RSI)
  • RPRX 56.61
  • SUI 53.88
  • Support Level
  • RPRX $36.03
  • SUI $124.30
  • Resistance Level
  • RPRX $41.24
  • SUI $126.42
  • Average True Range (ATR)
  • RPRX 1.17
  • SUI 2.68
  • MACD
  • RPRX 0.28
  • SUI 0.39
  • Stochastic Oscillator
  • RPRX 48.17
  • SUI 95.43

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

About SUI Sun Communities Inc.

Sun Communities is a residential REIT that focuses on owning manufactured housing and residential vehicle communities. The company currently owns a portfolio of 501 properties, which includes 337 manufactured housing communities and 164 residential vehicle communities. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.

Share on Social Networks: